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Background: HLAMatchmaker is a program to analyze the epitope specificities of HLA
antibodies. It considers each HLA allele as a string of eplets. Intralocus and interlocus
comparisons between donor and recipient alleles offer a structural assessment of
compatibility and an analysis of allele panel reactivity patterns can generate information
about epitope specificities of HLA antibodies. However, HLAMatchmaker cannot always
generate conclusive interpretations of reactivity patterns of all monospecific antibodies,
which by definition recognize single epitopes.
Hypothesis:We have therefore developed a new antibody analysis approach that utilizes
the nonself–self algorithm of HLA epitope immunogenicity. It is based on the concept that
HLA antibodies originate fromB-cells with immunoglobulin receptors to self-HLA epitopes
on one given allele and which can be activated by epitopes defined by a few nonself
residue differences whereas the remainder of the structural epitope of the immunizing
allele consists of self residues.
Methods: Three human monoclonal class I antibodies from HLA typed women sensitized
during pregnancy were tested in Ig-binding assays with single alleles on a Luminex
platform.
Findings: Three new HLA epitopes were identified; they are defined by combinations of
nonself- and self-residues for one allele of the antibody producer.
Conclusion: The nonself–self paradigm of HLA epitope immunogenicity offers a second
approach to analyze HLA antibody specificities.
Keywords: HLAMatchmaker, HLA epitope, nonself–self algorithm, HLA antibody specificity, structural epitope
Introduction
The determination of epitope specificities of HLA antibodies offers a powerful approach to assess
mismatch acceptability for sensitized recipients. Such epitopes can be described structurally with
amino acids in HLA sequence positions. Alleles with epitopes recognized by patient’s antibodies
pose an increased risk and may be considered unacceptable mismatches and alleles that lack such
epitopes would be acceptable mismatches.
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EachHLA allele represents a collection of epitopes with distinct
molecular structures defined by immunochemical concepts that
address two issues: antigenicity, i.e., the reactivity of epitopes with
HLA antibodies and immunogenicity, i.e., the ability of epitopes
to induce specific antibodies (1, 2). An understanding of HLA
epitope antigenicity must be based on general concepts of how
antibody binds to a protein epitope. Three heavy chain and three
light chain complementarity determining region loops (CDR-H1,
-H2, -H3, -L1, -L2, and -L3) define the binding face (or paratope)
of antibody. They interact with a protein epitope that consists of
multiple amino acid residues distributed on a molecular surface
of 700–900Å2. There are about 15–25 contact residues in what
has been referred to as a structural epitope and a centrally located
so-called functional epitope consisting of a few residues that bind
with CDR-H3, which plays a dominant role in specific binding
(3–6).
HLAMatchmaker considers an eplet as the equivalent of a
functional epitope and additional residueswithin a radius of about
15Å in the corresponding structural epitope are necessary for
the binding with antibody (7). Eplets are small configurations of
polymorphic amino acid residues generally within a 3-Å radius
and they play a dominant role in the specificities of HLA epitopes.
EachHLA allele is viewed as a string of eplets and donor–recipient
compatibility is assessed through comparisons between donor and
recipient eplet strings.
Many studies with informative antibodies have led to a large
array of experimentally verified HLA epitopes. The website based
International Registry of HLA Epitopes1 has listings of antibody-
verified epitopes (8–11). One group corresponds solely to a sin-
gle eplet, i.e., all eplet-carrying alleles react with antibody and
the remaining alleles in the panel are non-reactive. The second
group of antibody-verified epitopes is defined by eplets that are
paired with other amino acid configurations within the structural
epitope. Interestingly, such configurations are generally shared
between the immunizing allele and at least one allele of the
antibody producer (12, 13). This suggests that the alloantibody
response to an HLA mismatch has an autoreactive component
and recent reports have expanded this view to the so-called
nonself–self paradigm of HLA epitope immunogenicity (14, 15).
This paradigm is based on the hypothesis that B-lymphocytes
carry low-affinity immunoglobulin B-cell receptors (BCRs) for
self-HLA epitopes. Their interactions with self-HLA will not lead
to B-cell activation or antibody production. In contrast, exposure
to HLA mismatches can induce a strong alloantibody response,
which is the result of a productive interaction of a BCR with a
nonself eplet whereby the remainder of the structural epitope on
the immunizing antigen must be identical or very similar to the
corresponding self-HLA epitope of the antibody producer.
HLAMatchmaker has successfully been used to determine epi-
tope specificities of many HLA antibodies especially in con-
junction with HLA typing data about antibody producer and
immunizer, which provides useful information about the mis-
matched epitopes presented during the immunizing event (2,
16). This algorithm considers eplets shared between the alleles
of the immunizer and antibody producer as intralocus and/or
interlocus matches, which cannot elicit antibody responses. Our
1http://www.epregistry.com.br
experience has, however, also shown that HLAMatchmaker can
give inconclusive interpretations of the epitope specificities of
certain HLA antibodies including human monoclonal antibodies
(mAbs), which by definition recognize single epitopes.
We have therefore developed for such antibodies an alternative
analysis program, which is based on the nonself–self paradigm
of immunogenicity of eplets on immunizing alleles. This report
describes the epitope specificity analysis of three human mAbs
tested with HLA class I single allele beads (SABs) in antibody
binding assays on a Luminex platform.
Materials and Methods
Human Monoclonal Antibodies
Human HLA class I mAbs were obtained from cloned hybrido-
mas generated from Epstein–Barr virus transformed B-cells from
women who became sensitized during pregnancy by paternal
HLA antigens of their children as previously described (17). These
antibodies offer two advantages over sera from sensitized patients:
they recognize single epitopes and they are in culture supernatants
without interfering factors that can be present in sera. HLA types
of antibody producer and immunizer and HLA sequence data
provide information about self- and nonself residues of structural
epitopes presented during the immunizing event.
Antibody Reactivity Assays
These were done using immunoglobulin-binding assays with SAB
from two commercial vendors (One Lambda Inc., Canoga Park,
CA, USA; Immucor, Life Codes Corporation, Stamford, CT, USA)
according to manufacturer’s instructions. In brief, an aliquot of an
SABmixture was incubated with a small volume of antibody, then
washed to remove unbound antibody. Anti-human immunoglob-
ulin (IgG or IgM) antibody conjugated to phycoerythrin was
added; after incubation, the bead mixture was diluted for analysis
on a Luminex 100 instrument (Luminex, Austin, TX, USA) and
the reactivity was determined with the manufacturer’s software.
Median fluorescence intensity (MFI) values were recorded for
each allele and the positive and negative control beads. All mAbs
showed extremely low MFI values (mostly <100) with the self-
alleles of the antibody producer.
Design of the Antibody Reactivity Analysis
Program Based on the NonSelf–Self Paradigm of
HLA Epitope Immunogenicity
This paradigm considers the nonself–self theory of the immune
response originally forwarded by Burnet (18) and extensively
discussed and modified by many investigators (19–23). During
B-cell development, rearrangements of VH and VL genes produce
diversity in the antigen-binding sites of immunoglobulins. These
processes lead to the expression of immunoglobulin receptors on
developing B-cells, which go through several stages to become
mature lymphocytes with BCRs that can recognize epitopes on
autologous proteins. Lymphocytes with high-avidity BCRs disap-
pear after positive and negative selection and receptor editing and
the remaining B-cells carry only low-avidity BCRs so that their
interactions with self-epitopes on autologous proteins will not
induce their activation. B-cell responses leading to antibodies can-
not be triggered by every foreign entity, but it requires a “criterion
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of continuity” of antigenic patterns, which discriminate nonself
from self (22). In other words, the immune system does not react
to self-molecules, but will respond to certainmodifications within
self-molecules.
We have previously hypothesized that B-cells carry low-affinity
receptors for self-HLA epitopes, which can interact with non-
self residue configurations provided that the remainder of the
structural epitope of the immunizing HLA antigen consists of
self-residues (1, 14). It is well-known that among the six CDRs
immunoglobulins, the centrally located CDR-H3 binds to a func-
tional epitope and plays a pivotal role in determining anti-
body specificity. CDR-H3 has a considerably longer amino acid
sequence than the other CDRs and displays significant sequence
variability and structure (24, 25). According to our hypothesis,
CDR-H3 has a loop configuration with very low binding ability
with a self-HLA functional epitope but it can refold to yield
another configuration that can specifically recognize a nonself
functional HLA epitope whereas the other CDRs bind to self-
configurations shared between the immunizing antigen and an
allele of the antibody producer. This concept raises the require-
ment that the immunizing HLA antigen must have one dis-
tinct nonself amino acid configuration (the mismatched eplet),
whereas the other amino residues contacted by antibody should
be the same or very similar as those on a self-HLA antigen
of the antibody producer. Three publications describe exper-
imental evidence, which supports our hypothesis (1, 14, 15).
For each antibody response, at least one allele of the antibody
producer has no or few differences with the immunizing allele
in antibody-accessible positions defined by a 15Å radius of
the mismatched eplet, the presumed dimension of a structural
epitope.
This antibody reactivity analysis has three steps in the speci-
ficity determination of monospecific antibodies. Step 1: identify
from amino acid sequences, which residues (not eplets) on the
molecular surface of the immunizing allele are nonself for at least
one HLA-A, HLA-B, or HLA-C allele of the antibody producer
but are self for other alleles of the antibody producer. This step
applies the concept that the antibody has originated from a B-
cell with a BCR specific for a self-epitope on one of the HLA
alleles of the antibody producer. Step 2: select nonself residue(s) of
the immunizing allele, which are present on all antibody-reactive
alleles in the SAB panel; none of the reactive alleles can have
a different residue in that sequence position. This step applies
the concept that a monospecific antibody recognizes an epitope
defined by the selected nonself residue presented by the immu-
nizing allele. Some non-reactive SAB alleles including those of
the antibody producer will have the same nonself residue but
within the corresponding structural epitope, they have certain
residue configurations that interfere with antibody binding. Step
3: within a 15Å radius, compare the residue compositions of
nonself-carrying reactive and non-reactive alleles including those
of the antibody producer. These comparisons are designed to
identify residues associated with a lack of binding with anti-
body. They permit molecular descriptions of antibody-specific
epitopes defined by nonself residues combined with distinct
configurations of self-residues within the context of structural
epitopes.
Structural Modeling of Epitopes
Residue locations defining epitopes on the HLA molecular sur-
face were visualized with crystallographic models downloaded
from the Entrez Molecular Modeling Database (MMDB) on the
National Center for Biotechnology Informationwebsite2. Thiswas
done with the Cn3D structure and sequence alignment software
program, which can show selected residues and has a “select
by distance” (in Ångstroms) command that allows the user to
determine how far residues are apart. (26).
Results
Tables 1–3 show the MFI values of the SAB panel and the amino
acid residues used to determine the epitope specificities of the
mAbs. As a visual tool for this analysis, these residues are color
coded. Nonself residues presented by the immunizing alleles are
in yellow boxes and self-residues that are shared between the
immunizer and the alleles of the antibody producer are in blue
boxes. Residues associated with negative reactions of panel alleles
are in orange red boxes. Some reactive alleles have in certain
sequence positions different residues than the immunizing allele;
such permissive residue substitutions are in green boxes.
An Epitope Defined by 142I145R+ 138M+
79G80T82R83G
The A*11:01-induced HU-62 mAb (MUL7-C7, IgM) reacted
with 20 HLA-A alleles MFI values ranging from 14,523 to 2,797
(Table 1). The immunizing A*11:01 (indicated in the table as
IMM) has 142I and 145R that are shared with the antibody-
reactive alleles. The 142I145R combination is mismatched for
A*02:06, which has 142T145H but the other alleles of the anti-
body producer have 142I145R. According to the nonself–self
algorithm of HLA epitope immunogenicity, HU-62 antibodies
must have originated fromB-cells with BCRs toward a 142T145H-
defined self-epitope on HLA-A*02:06 and which responded to
the nonself 142I145R on the immunizing A*11:01. However,
why does HU-62 not react with so many 142I145R-carrying
alleles including those of the antibody producer? An analysis
of residues within 15Å of 142I145R indicated an important
role of sequence position 138. The immunizing A*11:01 and
all reactive HLA-A alleles have a methionine (138M) residue.
In contrast, the non-reactive HLA-B and HLA-C alleles all
of which have 142I145R, carry either a threonine (138T) or
a lysine (138K) residue; they include B*18:01, B*51:01, and
C*12:03 of the antibody producer. This suggests that 138M is a
required component of the 142I145R-defined epitope recognized
by HU-62. However, the 142I145R+ 138M-carrying A*25:01 of
the antibody producer and four more alleles in the SAB panel
(A*23:01, A*24:02, A*24:03, and A*32:01) were non-reactive.
They share the 79G80I82L83R combination, whereas the reac-
tive alleles have 79G80T82R83G. These findings suggest that
HU-62 is specific for an epitope defined by the combination of
142I145R+ 138M+ 79G80T82R83G. Figure 1 (left) shows the
locations of these residues on a molecular model of A*11:01; all
of them are <10Å from each other.
2http://www.ncbi.nlm.nih.gov/Structure
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TABLE 1 | HU-62 is specific for an epitope defined by 142I145R+138M+79G80T82R83G.
HU-62 MUL7-C7 MFI Nonself Nonself Self Self Self Self Self
79G
79G
79R
79G
79R
79G
79G
79G
79G
79G
79G
79G
79G
79G
79G
79G
79G
79G
79G
79G
79G
79G
79G
79G
79G
79G
79R
79R
79R
79R
79G
79G
79G
79G
79G
80T
80T
80I
80T
80I
80T
80K
80T
80T
80T
80T
80T
80T
80T
80T
80T
80T
80T
80T
80T
80T
80T
80T
80T
80T
80T
80I
80I
80I
80I
80T
80T
80T
80T
80T
82R
82R
82L
82R
82L
82R
82R
82R
82R
82R
82R
82R
82R
82R
82R
82R
82R
82R
82R
82R
82R
82R
82R
82R
82R
82R
82L
82L
82L
82L
82R
82R
82R
82R
82R
83G
83G
83R
83G
83R
83G
83G
83G
83G
83G
83G
83G
83G
83G
83G
83G
83G
83G
83G
83G
83G
83G
83G
83G
83G
83G
83R
83R
83R
83R
83G
83G
83G
83G
83G
A*11:01 IMM
A*02:06 Self
A*25:01 Self
B*18:01 Self
B*51:01 Self
C*12:03 Self
C*15:02 Self
A*11:02
A*30:01
A*31:01
A*03:01
A*29:01
A*29:02
A*33:03
A*01:01
A*34:02
A*33:01
A*36:01
A*80:01
A*74:01
A*66:01
A*26:01
A*34:01
A*43:01
A*66:02
A*30:02
A*23:01
A*24:02
A*24:03
A*32:01
A*02:01
A*02:03
A*68:01
A*68:02
A*69:01
50 HLA-B alleles
15 HLA-C alleles
13720
28
9
10
12
29
15
14523
14028
13898
13870
13596
13297
13083
13049
12728
12058
11719
11501
9508
9270
9240
6772
6679
6640
2797
146
122
67
8
22
12
335
96
120
26 ± 51
20 ± 5
142I
142T
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142T
142T
142T
142T
142T
142I
142I
145R
145H
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145H
145H
145H
145H
145H
145R
145R/L
138M
138M
138M
138T
138T
138T
138T
138M
138M
138M
138M
138M
138M
138M
138M
138M
138M
138M
138M
138M
138M
138M
138M
138M
138M
138M
138M
138M
138M
138M
138M
138M
138M
138M
138M
138T
138K/T
Not surprisingly, the 142T145H-carrying A*02, A*68, and
A*69 alleles were non-reactive although all of them have
138M+ 79G80T82R83G. It should be noted that these residues
are shared between the immunizing A*11:01 and A*02:01 of
the antibody producer. These findings suggest that the HU-62
antibody response was initiated by an antigen with a small residue
difference (142I145R versus 142T145H) whereas the rest of the
epitope consisted of self-residues.
An Epitope Defined by 142I144Q145R+ 80I or 80T
The A*32:01-induced mAb HU-22 (HDG2-G7, IgG) reacted
with 16 additional HLA-A alleles and 17 HLA-B alleles; their
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TABLE 2 | HU-22 is specific for an epitope defined by 142I144Q145R+80I
or 80T.
A*32:01 IMM
A*02:01 self
A*24:02 self
B*07:02 self
B*40:01 self
C*03:04 self
C*07:02 self
A*23:01
A*25:01
A*31:01
A*30:01
B*53:01
A*33:03
A*34:02
A*29:01
A*33:01
B*51:02
A*29:02
B*38:01
B*51:01
A*66:01
B*15:16
B*59:01
B*57:03
A*66:02
A*26:01
A*74:01
B*52:01
B*15:13
A*30:02
A*34:01
B*44:02
B*49:01
B*44:03
B*27:05
A*43:01
B*57:01
B*37:01
B*58:01
B*47:01
29 HLA−B alleles
14 HLA−C alleles
B*13:01/02
7 HLA−A alleles
5 HLA−A alleles
HU-22 HDG2-G7
21268
5
13
8
18
22
20
21369
20516
17890
15330
13137
12678
11459
11214
10704
10585
9484
9469
9396
9036
8839
8630
8570
7735
7371
7350
7238
6916
6831
6365
5945
5919
5800
5372
5352
5081
4382
4116
3788
71 ± 90
26 ± 8
13 ± 12
8 ± 5
7 ± 3
MFI
142I
142T
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142I
142T
Self
144Q
144K
144K
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144Q
144K
144K
Nonself
145R
145H
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145R
145L
145R
145H
Self
80I
80T
80I
80N
80N
80N
80N
80I
80I
80T
80T
80I
80T
80T
80T
80T
80I
80T
80I
80I
80T
80I
80I
80I
80T
80T
80T
80I
80I
80T
80T
80T
80I
80T
80T
80T
80I
80T
80I
80T
80N
80N/K
80T
80T
80T
Self
138M
138M
138M
138T
138T
138T
138T
138M
138M
138M
138M
138T
138M
138M
138M
138M
138T
138M
138T
138T
138M
138T
138T
138T
138M
138M
138M
138T
138T
138M
138M
138T
138T
138T
138T
138M
138T
138T
138T
138T
138T
138T
138T
138M
138M
Self
*Self- and nonself residue assignments are based on A*24:02 of the antibody producer.
TABLE 3 | HU-57 is specific for an epitope defined by 69T70N71T+
80N82R83G.
HU-57 DMS4-G2
IMM
self
self
self
self
self
self
B*15:01
A*03:01
A*68:01
B*07:02
B*51:01
C*07:02
C*15:02
B*15:12
B*40:01
B*15:03
B*18:01
B*40:02
B*41:01
B*15:02
B*45:01
B*35:01
B*39:01
B*08:01
B*78:01
B*35:08
B*50:01
B*15:18
B*07:03
B*48:01
B*14:05
B*14:06
B*15:13
B*38:01
B*49:01
B*52:01
B*53:01
B*13:02
B*37:01
B*44:02
B*44:03
B*47:01
9 HLA-B alleles
5 HLA-B alleles 
27 HLA-A 
alleles
17 HLA-C 
alleles
MFI
18413
294
283
225
375
316
338
17902
17895
17751
17182
16895
16736
15739
14551
13459
14369
14177
13570
11639
9797
9766
9660
8970
5362
2531
325
534
457
344
330
409
705
466
856
344
295 ± 55
313 ± 35
306 ± 31
359 ± 27
Nonself
69T
69A
69A
69A
69T
69R
69R
69T
69T
69T
69T
69T
69T
69T
69T
69T
69T
69T
69T
69T
69T
69T
69T
69T
69T
69T
69T
69T
69T
69T
69T
69T
69T
69T
69T
69T
69A/R
69A
69A
69R
Nonself
70N
70Q
70Q
70Q
70N
70Q
70Q
70N
70N
70N
70N
70N
70N
70N
70N
70N
70N
70N
70N
70N
70N
70N
70N
70N
70N
70N
70N
70N
70N
70N
70N
70N
70N
70N
70N
70N
70K/Q
70S
70H/Q
70Q
Nonself
71T
71S
71S
71A
71T
71A
71A
71T
71T
71T
71T
71T
71T
71T
71T
71T
71T
71T
71T
71T
71T
71T
71T
71T
71T
71T
71T
71T
71T
71T
71T
71T
71T
71T
71T
71T
71A
71A
71S
71A
Self
80N
80T
80T
80N
80I
80N
80K
80N
80N
80N
80N
80N
80N
80N
80N
80N
80N
80N
80N
80N
80N
80N
80N
80N
80N
80N
80I
80I
80I
80I
80I
80T
80T
80T
80T
80T
80N
80I
80T
80K/N
Self
82R
82R
82R
82R
82L
82R
82R
82R
82R
82R
82R
82R
82R
82R
82R
82R
82R
82R
82R
82R
82R
82R
82R
82R
82R
82R
82L
82L
82L
82L
82L
82L
82L
82L
82L
82L
82R
82L
82L
82R
83G
83G
83G
83G
83R
83G
83G
83G
83G
83G
83G
83G
83G
83G
83G
83G
83G
83G
83G
83G
83G
83G
83G
83G
83G
83G
83R
83R
83R
83R
83R
83R
83R
83R
83R
83R
83G
83R
83R
83G
Self
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FIGURE 1 | Locations of residues (in yellow) defining the HU-62, HU-22, and HU-57 epitopes. The HLA-bound peptide is in brown and β2-microglobulin is in
blue.
MFI values ranged from 21,369 to 3,788 (Table 2). An analysis
of the nonself residues shared between the immunizing allele
and the antibody-reactive alleles showed that 142I, 144Q, and
145R are nonself for the antibody producer’s A*02:01, which
has 142T,144K, and 145H whereas 144Q alone is nonself for
the antibody producer’s A*24:02, which has 144K. This sug-
gests that HU-22 recognizes an epitope that might be struc-
turally similar to the HU-62 epitope, which is defined by
142I145R+ 138M+ 79G80T82R83G. HU-22, however, reacted
with both HLA-A and HLA-B alleles and this rules out 138M
as a critical component of this epitope. Another difference is
that the HU-22 epitope requires 142I144Q145R as indicated by
the non-reactive B*13 alleles, which have 142I144Q145L and the
non-reactivity of all seven 142I144K145R-carrying HLA-A alleles
(bottom of Table 2). Sequence position 80 appears to play an
important role in the HU-22 epitope. The immunizing A*32:01
has 80I and the reactive alleles have either 80I or 80T, which
suggests that 80T is a permissible residue substitution that does
not significantly affect the reactivity with HU-22. In contrast, all
29 non-reactive 142I144Q145R-carrying HLA-B alleles have 80N
and all HLA-C alleles, which have 142I144Q145R with either 80N
or 80K are non-reactive thereby suggesting that these residues
prevent binding with HU-22.
As noted above, the antibody-reactive alleles showed a wide
range ofMFI values from 21,369 to 3,788. Does this reflect residue
differences within the structural epitope that corresponds to
142I144Q145R? The averageMFI values for 80I and 80T-carrying
reactive alleles were similar (9108 5778 versus 8122 3781,
p= 0.24 by Student’s t-test). On the other hand, alleles with
138M (which was presented by the immunizing A*11:01) were
significantly more reactive than the 142I144Q145R-carrying alle-
les that have 138T (10678 5778 versus 7146 2567, p= 0.008).
Within the 138M or 138T groups, there were also differences
between 80I (which was presented by the immunizing A*11:01)
and 80T namely 21051 466 versus 9914 3584, p< 0.0001
and 8361 2486 versus 4835 936, p= 0.0008, respectively.
These findings show that these residue differences decrease
the MFI values but not to an extent that they reflect negative
reactions.
In conclusion, HU-22 is specific for an epitope defined by
142I144Q145R combinedwith 80I or 80T. This epitope is depicted
in Figure 1 (middle). According to the nonself–self paradigm
of HLA epitope immunogenicity, it seems likely that HU-22
originated from B-cells with BCRs specific for a self-epitope on
A*24:02 of the antibody producer and the immunizing A*32:01
had the nonself 144Q together with the self 142I, 145R, and 80I
residues. Another explanation is that HU-22might have been pro-
duced by B-cells with BCRs specific for a self-epitope on A*02:01.
In such case, the immunizing A*32:01 presented a nonself
142I144Q145R together with a separate nonself 80I residue that
would have made contact with a different CDR of antibody.
An Epitope Defined by 69T70N71T+ 80N82R83G
The B*15:01-induced HU-57 (DMS4G2, IgG) reacted only with
alleles that share the combination of the 69T70N71T and
80N82R83G configurations; all other alleles lack this combination
and are essentially non-reactive (Table 3). It should be noted that
B*51:01 of the antibody producer has 69TNTwhereas B*07:02 and
C*07:02 have 80NRG. Fromwhich autoreactive B-cells didHU-57
originate? There are two possibilities. First, the antibody producer
had B-cells with BCRs specific for a 69A70Q71A-defined self-
epitope on B*07:02 and 69T70N71T on the immunizing B*15:01
was recognized as nonself whereas 80N82R83G is self. Second,
HU-57 could have originated from B-cells with BCRs for the
80I82L83R-defined self-epitope on B*51:01 of the antibody pro-
ducer and the nonself 80N82R83G on the immunizing B*15:01-
induced activation. All 10 HLA-B alleles with 69T70N71T but not
80N82R83G and all 9 HLA-B alleles with 80N82R83G but not
69T70N71T were considered non-reactive but we noted slightly
higher MFI values for the first group: 477 178 versus 295 55,
p= 0.01 (t-test). This finding seems to favor the possibility that
HU-57 originated from B*07:02 autoreactive B-cells. Figure 1
(right) shows the molecular locations of the residues that define
the HU-57 epitope on B*35:01.
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TABLE 4 | Polymorphic residue comparisons between mAb defined and corresponding self-HLA structural epitopes.
HU-62
HU-22
HU-57
mAb
A*11:01 epitope
A*02:01 self BCR
A*32:01 epitope
A*24:02 self BCR
B*15:01 epitope
B*07:02 self BCR
Immunizing Event
142I145R + 138M + 79G80T82R83G
142T145H
142I144Q145R + 80I or 80T
142I144K145R
69T70N71T + 80N82R83G
69A70Q71A
Epitope Description
76V
76V
76E
76E
43P
43P
79G
79G
79R
79R
44R
44R
80T
80T
80I
80I
59Y
59Y
81L
81L
81A
81A
62R
62R
82R
82R
82L
82L
65Q
65Q
83G
83G
83R
83R
66I
66I
127N
127K
127N
127K
73T
73T
131R
131R
131R
131R
76E
76E
138M
138M
138M
138M
79R
79R
147W
147W
147W
147W
80N
80N
149A
149A
149A
149A
81L
81L
150A
150A
150A
150A
147W
147W
151H
151H
151R
151H
163L
163E
73T
73T
73T
73T
19E
19E
Polymorphic surface residues within 15 Ångstroms
Polymorphic Residue Comparisons Between
Structural Alloepitopes and Self-Epitopes
The nonself–self algorithmofHLA epitope immunogenicityman-
dates that an immunizing epitope has a nonself residue compo-
nent, which in the context of the structural epitope is surrounded
by a residue configuration that is the same or very similar to
that of a self-epitope on an HLA allele of the antibody producer.
The 15Å radius is an estimate of the dimension of a structural
epitope (7). Table 4 shows the polymorphic residues on the
molecular surface within 15Å of nonself configurations of the
epitopes recognized by each of these three mAbs in comparison
with the corresponding self-epitope on an HLA allele of the anti-
body producer who presumably had B-cells with the appropriate
self-BCRs.
For the A*11:01-induced epitope recognized by HU-62, posi-
tion 127 is the only one among 14 polymorphic residue posi-
tions with a difference with the antibody producer’s A*02:01
namely, 127N versus 127K. The SAB panel had no informa-
tive alleles, which could have assessed the influence of 127N
and 127K on the epitope recognized by HU-62. For the HU-22
epitope, the immunizing A*32:01 and the antibody producer’s
A*24:02 have differences in two positions: 127N versus 127K
and 151R versus 151H. Since neither residue difference had
any significant influence on the HU-22 reactivity with the SAB
panel (data not shown), it seems unlikely that they influence
the structural epitope recognized by HU-22. For the B*15:01-
induced HU-57 epitope, there is only one position with a residue
difference: 163L versus 163E. Alleles with different residues in
position 163 were equally reactive with HU-57 (data not shown)
thereby suggesting no significant role in the epitope recognized by
HU-57.
It should be noted that there also are monomorphic residues
within the 15Å radius of a nonself residue configuration (data
not shown); such residues are always self. Consistent with the
nonself–self algorithm of HLA epitope immunogenicity, these
findings indicate a very high degree of selfness of the residues
surrounding a nonself residue configuration of an immunizing
HLA epitope.
Discussion
This report describes the epitope specificities of three human
mAbs determined with a new approach that is based on
the nonself–self paradigm of HLA epitope immunogenicity.
Although HLAMatchmaker is generally considered an effective
program for the epitope specificity analysis of HLA antibodies,
our experience has shown that for certainmAbs it does not permit
a precise specificity determination. HLAMatchmaker considers
each allele as a string of eplets covering the entire sequence of
polymorphic residues and matching is done by intralocus and
interlocus comparisons between donor and recipient strings. A
donor eplet that is also present on any of the recipient alleles is
considered a match and according to HLAMatchmaker cannot
induce antibodies.
There are, however, exceptions, which can be explained with
the hypothesis that each HLA antibody population originates
from an immature B-cell with BCRs specific for a given struc-
tural self-epitope defined by residues of an HLA allele of the
recipient. Each recipient has a repertoire of B-cells with BCRs
for various self-HLA epitopes. A donor allele can activate certain
autoreactive B-cells provided it presents an epitope with some
distinct residue differences but is otherwise structurally similar
to the recipient’s self-epitope. In other words, an immunizing
HLA epitope must have one or few nonself residues surrounded
by self residues in context with the corresponding structural
self-epitope of the antibody producer. Previous reports of HLA-
Matchmaker identified epitopes have indeed shown that within a
15Å radius antibody-reactive eplets are surrounded by residues
shared with at least one of the alleles of the antibody producer
(1, 14, 15).
This report gives examples of the situation whereby the non-
self residue part of the immunizing epitope can be found on
one allele but not the other alleles of the antibody producer.
For HU-62, for instance, the immunizing A*11:01 presents
142I145R as nonself for A*02:06 of the antibody producer but
this configuration is also present on her HLA-B and HLA-
C alleles (Table 1). According to HLAMatchmaker, 142I145R
would be an interlocus match. HU-57 is another example:
B*15:01 presents 69T70N71T as a mismatch for B*07:02 but
this configuration would be considered as an intralocus match
for B*51:01 of the antibody producer (Table 3). This enigma
can be resolved by considering the data that these epitopes are
defined by the overall combinations of nonself and self residue
configurations.
Accordingly, HU-62 is specific for an epitope defined by the
nonself 142I145R in combination with two self-configurations:
138M and 79G80T82R83G (Table 1) and HU-57 recognizes
an epitope defined by nonself 69T70N71T+ self 80N82R83G
(Table 3). Interestingly, HU-22 is specific for an epitope that is
defined by nonself 142I144Q144R combined with self 80I and self
138M (for the antibody producer’s A*24:02) but 80T and 138T
are permissible substitutions that have only a minor effect on the
binding with antibody (Table 2).
It should be noted that in all three tables, the reactive alleles
in the panel showed wide ranges of MFI values. Certain alleles
may have other structural differences with the immunizing allele,
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which cause lowerMFI values but which should still be considered
as positive. A discussion of these concepts is beyond the scope of
this paper.
Altogether, this study has yielded three new epitopes, which can
only be defined by combinations of nonself and self residues for
one allele of the antibody producer. Theywill be added to the list of
antibody-verified HLA class I epitopes in the International HLA
epitope registry. Each epitope has a distinct residue description
that will be converted to eplet combinations, which can be used
in the HLAMatchmaker analysis of epitope specificities of HLA
antibodies.
The nonself–self paradigm of HLA epitope immunogenicity
offers a new alternative approach to investigate the specificities
of antibodies with complex reactivity patterns. It may also offer
opportunities to study antibody responses to HLA mismatches in
a transplant setting.
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